Related Experiment Video
Updated: May 5, 2026
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Blood-based biomarkers for the optimization of anti-angiogenic therapies
Cristina Rabascio1, Francesco Bertolini
1Laboratory of Hematology-Oncology, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy. cristina.rabascio@ieo.it.
Abstract:
The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for therapy. Strategies have been pursued to inhibit neovascularization and to destroy existing tumor vessels, or both. These include direct targeting of endothelial cells, and indirect targeting by inhibiting the release of proangiogenic growth factors by cancer or stromal cells. Many patients benefit from antiangiogenic therapies; thus, development of noninvasive biomarkers of disease response and relapse is a crucial objective to aid in their management. A number of non-invasive tools are described with their potential benefits and limitations. We review currently available candidate biomarkers of anti-angiogenic agent effect. Including these markers into clinical trials may provide insight into appropriate dosing for desired biological effects, appropriate timing of additional therapy, and prediction of individual response. This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various other diseases.
Insights
Targeting tumor angiogenesis, the process of new blood vessel growth, is key for cancer therapy. Noninvasive biomarkers are crucial for monitoring patient response to anti-angiogenic treatments and improving cancer management.
Area of Science:
- Oncology
- Vascular Biology
- Biomarker Development
Background:
- Tumor growth and metastasis rely on blood vessels, making tumor angiogenesis a therapeutic target.
- Anti-angiogenic therapies offer benefits to many cancer patients.
- Effective management requires noninvasive biomarkers to assess treatment response and detect relapse.
Purpose of the Study:
- To review noninvasive biomarkers for monitoring anti-angiogenic therapy effects.
- To discuss the potential benefits and limitations of these candidate biomarkers.
- To highlight the importance of biomarkers in clinical trials for optimizing cancer treatment.
Main Methods:
- Review of literature on noninvasive biomarkers for anti-angiogenic therapy.
- Analysis of candidate biomarkers for assessing anti-angiogenic agent effects.
- Discussion of the integration of biomarkers into clinical trial design.
Main Results:
- Several noninvasive tools show promise for monitoring anti-angiogenic therapy.
- Biomarkers can inform dosing, treatment timing, and individual response prediction.
- These markers are vital for optimizing current cancer treatments and drug discovery.
Conclusions:
- Noninvasive biomarkers are essential for effective clinical use of angiogenesis inhibitors.
- Biomarker integration aids in personalized cancer therapy and drug development.
- This research has implications for optimizing cancer treatment and exploring new therapeutic avenues for various diseases.
More Related Videos
09:33Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...